# reload+after+2024-01-21 14:46:25.350254
address1§512 2nd Street
address2§4th Floor
city§San Francisco
state§CA
zip§94107
country§United States
phone§650 243 5555
website§https://olema.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1b/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
fullTimeEmployees§70
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Sean P. Bohen M.D., Ph.D.', 'age': 56, 'title': 'President, CEO & Director', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 1001770, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Shane William Charles Kovacs M.B.A.', 'age': 49, 'title': 'Chief Operating & Financial Officer', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 726170, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Naseem  Zojwalla M.D.', 'age': 50, 'title': 'Chief Medical Officer', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 775477, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Geoffrey  Mogilner', 'title': 'Vice President of Investor Relations & Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Julie  Dexter', 'title': 'Senior VP & Head of People', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. David C. Myles Ph.D.', 'age': 60, 'title': 'Chief Discovery & Non-Clinical Development Officer', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 200000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Demiana  Faltaos Ph.D., Pharm.D.', 'title': 'VP & Head of Clinical Pharmacology', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. John B. Moriarty Jr., J.D.', 'age': 55, 'title': 'Corporate Secretary', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 434324, 'exercisedValue': 0, 'unexercisedValue': 10904116}, {'maxAge': 1, 'name': 'Ms. Sasha  Austin CPA', 'title': 'VP of Finance & Controller', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§6
boardRisk§6
compensationRisk§9
shareHolderRightsRisk§8
overallRisk§8
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§2.214
currency§USD
dateShortInterest§1702598400
forwardEps§-2.16
exchange§NMS
quoteType§EQUITY
shortName§Olema Pharmaceuticals, Inc.
longName§Olema Pharmaceuticals, Inc.
firstTradeDateEpochUtc§1605796200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§435c746d-8ba5-3a9e-8724-ea5906efb2d8
gmtOffSetMilliseconds§-18000000
targetHighPrice§28.0
targetLowPrice§21.0
targetMeanPrice§25.14
targetMedianPrice§25.0
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§7
quickRatio§17.39
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
